Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HepBTer terbinafine in chronic hepatitis B
2024-514888-25-00Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Terbinafine in Chronic Hepatitis B (CHB) (4 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: HBsAg decline and HBV DNA decline in Group A. Started Jul 2024; status: completed.
02
Drugs
Terbinafine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2024-514888-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514888-25-00.